MER-101
MER-101 is in Phase II development for the treatment of Bone Metastases associated with solid tumours.
MER-101 is a bisphosphonate (zoledronic acid) compound for metastatic bone disease. Because of poor bioavailability, the bisphosphonate products available and indicated for oncology indications are usually administered by intravenous infusion. The sales of zoledronic acid as an intravenous infusion were $1.3Bn in 2007.
Merrion uses GIPET™ technology to formulate a sufficiently bioavailable oral dosage form of the market leading bisphosphonate for bone metastases.
Having an orally available product brings several benefits over current infusion techniques:
- More convenient for patients
- Reduction in the administration costs of the drug
- Avoiding the risks of breaking the skin
- May allow additional patient populations access to the medication due to the simpler administration and the lower overall cost of administration
The proof of principle for a weekly oral formulation has been demonstrated in a patient population clinical study.
Clinical Data for MER-101 was presented at the AACR - NCI - EORTC International Conference on "Molecular Targets and Cancer Therapeutics" on the 24th Oct 2007 in San Francisco.
For more information or to view a copy of the poster, please click here.
Merrion is currently enrolling a Phase II oncology study, with sites in the US and in Europe.
